MX2017016400A - Vectores para uso en un sistema de coexpresion inducible. - Google Patents

Vectores para uso en un sistema de coexpresion inducible.

Info

Publication number
MX2017016400A
MX2017016400A MX2017016400A MX2017016400A MX2017016400A MX 2017016400 A MX2017016400 A MX 2017016400A MX 2017016400 A MX2017016400 A MX 2017016400A MX 2017016400 A MX2017016400 A MX 2017016400A MX 2017016400 A MX2017016400 A MX 2017016400A
Authority
MX
Mexico
Prior art keywords
vectors
inducible coexpression
coexpression system
inducible
expression
Prior art date
Application number
MX2017016400A
Other languages
English (en)
Other versions
MX390195B (es
Inventor
MCCLAIN Seah
Vlasek Mark
BARISH Philip
Minshull Jeremy
Original Assignee
Absci Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Absci Llc filed Critical Absci Llc
Publication of MX2017016400A publication Critical patent/MX2017016400A/es
Publication of MX390195B publication Critical patent/MX390195B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)
  • General Factory Administration (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Slot Machines And Peripheral Devices (AREA)
  • Preliminary Treatment Of Fibers (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La presente invención se refiere a vectores de expresión para uso en un sistema de coexpresión inducible, capaz de la inducción controlada de la expresión de cada producto génico.
MX2017016400A 2015-06-16 2016-06-16 Vectores para uso en un sistema de coexpresion inducible. MX390195B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14/740,475 US20150353940A1 (en) 2013-08-05 2015-06-16 Vectors for use in an inducible coexpression system
PCT/US2016/037942 WO2016205570A1 (en) 2015-06-16 2016-06-16 Vectors for use in an inducible coexpression system

Publications (2)

Publication Number Publication Date
MX2017016400A true MX2017016400A (es) 2018-03-02
MX390195B MX390195B (es) 2025-03-20

Family

ID=54769087

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017016400A MX390195B (es) 2015-06-16 2016-06-16 Vectores para uso en un sistema de coexpresion inducible.

Country Status (12)

Country Link
US (2) US20150353940A1 (es)
EP (2) EP3310919B1 (es)
JP (2) JP6976860B2 (es)
KR (1) KR102716963B1 (es)
CN (1) CN107849572A (es)
AU (2) AU2016278242B2 (es)
CA (1) CA2986443A1 (es)
DK (1) DK3310919T3 (es)
ES (1) ES2906725T3 (es)
IL (2) IL307555A (es)
MX (1) MX390195B (es)
WO (1) WO2016205570A1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12157766B2 (en) 2012-08-05 2024-12-03 Absci Corporation Cytoplasmic expression system
WO2017106583A1 (en) * 2015-12-15 2017-06-22 Absci, Llc Cytoplasmic expression system
AU2019349934B2 (en) 2018-09-25 2024-12-05 Absci Corporation Protein purification methods
KR20210090645A (ko) * 2018-11-05 2021-07-20 제넨테크, 인크. 원핵 숙주 세포에서 2개의 사슬 단백질을 생산하는 방법
CN111269294B (zh) * 2018-12-05 2023-03-28 广州中国科学院先进技术研究所 纤维寡糖转运蛋白LacY的突变位点、突变转运蛋白LacY及其制备方法和应用
CN111979206B (zh) * 2019-05-24 2021-08-17 深圳瑞德林生物技术有限公司 固定化融合酶及用其制备谷胱甘肽的方法
CR20230098A (es) * 2020-07-24 2023-08-07 Univ Duke Métodos y composiciones para la producción de productos derivados del acetil-coa
US20220380783A1 (en) * 2021-05-06 2022-12-01 Arizona Board Of Regents On Behalf Of Arizona State University Methods and system of managing resource competition in synthetic gene circuits
CN113528410A (zh) * 2021-06-23 2021-10-22 云舟生物科技（广州）有限公司 一种用于快速高效诱导表达外源蛋白的大肠杆菌工程菌及其制备方法与应用
WO2023114905A1 (en) 2021-12-16 2023-06-22 Absci Corporation Membrane-associated fusion proteins to increase the competency of cells
EP4448757A1 (en) 2021-12-17 2024-10-23 ABSCI Corporation Solid-phase screening for high-performing bacterial strains
CA3244071A1 (en) 2021-12-21 2023-06-29 Absci Corporation FOLA SELECTION ANALYSIS TO IDENTIFY STRAINS WITH INCREASED SOLUBLE TARGET PROTEIN EXPRESSION
CN118434853A (zh) 2021-12-23 2024-08-02 Absci公司 用于在宿主细胞中异源表达蛋白质的产物和方法
US20250059259A1 (en) * 2021-12-30 2025-02-20 Absci Corporation KNOCKOUT OF ptsP GENE ELEVATES ACTIVE GENE EXPRESSION
US20230268026A1 (en) 2022-01-07 2023-08-24 Absci Corporation Designing biomolecule sequence variants with pre-specified attributes
US20250383346A1 (en) 2022-06-29 2025-12-18 Absci Corporation Affinity screening method
WO2024040020A1 (en) 2022-08-15 2024-02-22 Absci Corporation Quantitative affinity activity specific cell enrichment
WO2024254237A1 (en) 2023-06-08 2024-12-12 Absci Corporation Solid-phase screening for high-performing bacterial strains
WO2025058962A1 (en) 2023-09-11 2025-03-20 Absci Corporation High-throughput methods for kinetic characterization, quantifying and optimizing antibodies and antibody fragments expression in bacteria
US12473370B2 (en) 2023-10-03 2025-11-18 Absci Corporation TL1A associated antibody compositions and methods of use
WO2025122885A1 (en) 2023-12-08 2025-06-12 Absci Corporation Anti-her2 associated antibody compositions designed by artificial intelligence and methods of use
WO2025144700A1 (en) 2023-12-27 2025-07-03 Absci Corporation Nanobody library screening using bacterial surface display

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3344618B2 (ja) 1997-06-20 2002-11-11 株式会社エイチ・エス・ピー研究所 シャペロン発現プラスミド
DE69841340D1 (de) * 1997-12-05 2010-01-07 Europ Lab Molekularbiolog Neue Methode zur Klonierung DNS unter Anwendung des E. coli RecE/RecT Rekombinationssystems
US6780405B1 (en) 2000-04-28 2004-08-24 Avant Immunotherapeutics, Inc. Regulated antigen delivery system (RADS)
US6979556B2 (en) * 2000-12-14 2005-12-27 Genentech, Inc. Separate-cistron contructs for secretion of aglycosylated antibodies from prokaryotes
AU2002245142B2 (en) * 2000-12-14 2007-07-05 Genentech, Inc. Prokaryotically produced antibodies and uses thereof
CN100513414C (zh) 2001-08-27 2009-07-15 杰南技术公司 进行抗体表达和装配的系统
WO2005040388A2 (en) * 2003-08-22 2005-05-06 Nucleonics Inc. Eukariotic expression systems for expression of inhibitory rna in multiple intracellular compartments
US8227241B2 (en) * 2004-03-12 2012-07-24 Unigene Laboratories, Inc. Bacterial host cell for the direct expression of peptides
DE102004061846A1 (de) * 2004-12-22 2006-07-13 Basf Ag Mehrfachpromotoren
MX2007015355A (es) 2005-06-06 2008-02-19 Dow Global Technologies Inc Sistemas promotores inducidos por manitol en celulas huesped bacterianas.
WO2007005837A2 (en) 2005-07-01 2007-01-11 The Regents Of The University Of California Inducible expression vectors and methods of use thereof
DK2155789T3 (da) 2007-05-01 2013-10-21 Res Dev Foundation Immunoglobulin-Fc-biblioteker
DK2240595T4 (da) 2008-01-03 2019-10-07 Cornell Res Foundation Inc Glykosyleret proteinekspression i prokaryoter
KR100958096B1 (ko) * 2008-02-11 2010-05-14 한국과학기술원 염색체 특정 부위 제거용 재조합 벡터 및 이를 이용한미생물 내 염색체 특정 부위의 제거방법
WO2010075956A1 (de) * 2008-12-16 2010-07-08 C-Lecta Gmbh Expressionsvektor
WO2010104938A1 (en) * 2009-03-10 2010-09-16 Athena Biotechnologies, Inc. Reducing carbon dioxide production and increasing ethanol yield during microbial ethanol fermentation
US8623652B2 (en) * 2009-04-06 2014-01-07 Lucigen Corporation Host-vector system for cloning and expressing genes
TR201803015T4 (tr) * 2009-11-19 2018-03-21 Glaxosmithkline Biologicals Sa Prokaryotik hücrelerde immünojenik polisakaridler üreten biyosentetik sistem.
US8603797B2 (en) * 2010-03-17 2013-12-10 Cornell University Methods and compositions for targeted mutagenesis in bacteria
EP2386641A1 (en) 2010-05-11 2011-11-16 Université Catholique De Louvain Method for extracellular production of recombinant biomolecules in a microorganism
CN104603274B (zh) * 2012-08-05 2020-08-18 Absci有限责任公司 可诱导共表达系统
WO2015020690A1 (en) * 2013-08-05 2015-02-12 Aronora, Inc. Coordinated coexpression of thrombin

Also Published As

Publication number Publication date
JP6976860B2 (ja) 2021-12-08
IL307555A (en) 2023-12-01
CN107849572A (zh) 2018-03-27
HK1253045A1 (zh) 2019-06-06
EP4039810A1 (en) 2022-08-10
CA2986443A1 (en) 2016-12-22
ES2906725T3 (es) 2022-04-20
EP3310919B1 (en) 2021-12-15
KR102716963B1 (ko) 2024-10-11
IL256094A (en) 2018-02-28
KR20180020213A (ko) 2018-02-27
AU2016278242A1 (en) 2018-01-18
DK3310919T3 (da) 2022-02-14
JP2018518957A (ja) 2018-07-19
IL256094B1 (en) 2023-11-01
AU2022228166A1 (en) 2022-09-29
US11371048B2 (en) 2022-06-28
EP3310919A4 (en) 2019-01-09
US20150353940A1 (en) 2015-12-10
IL256094B2 (en) 2024-03-01
US20160376602A1 (en) 2016-12-29
JP2021153600A (ja) 2021-10-07
WO2016205570A1 (en) 2016-12-22
AU2016278242B2 (en) 2022-06-09
EP3310919A1 (en) 2018-04-25
MX390195B (es) 2025-03-20

Similar Documents

Publication Publication Date Title
MX390195B (es) Vectores para uso en un sistema de coexpresion inducible.
MX2020002831A (es) Metodos y procesos para evaluacion no invasiva de variaciones geneticas.
IL264142A (en) Multispecific antibodies against cd40 and cd137
EP3278613A4 (en) Ofdma sounding for wlan system
MX2024015281A (es) Polinucleotidos de acido desoxirribonucleico (adn)/acido ribonucleico (arn) hibridos de repeticiones palindromicas cortas agrupadas regularmente separadas (crispr) y sus metodos de uso
BR112017009728A2 (pt) anticorpos isolados, ácido nucleico isolado, vetor, célula hospedeira, método para produzir o anticorpo, composição, usos de um anticorpo e métodos de tratamento de um distúrbio
MX2017015464A (es) Anticuerpos anti-tau y metodos de uso.
FR3033018B1 (fr) Piece de support d'element tubulaire, notamment pour aeronef.
CL2016003278A1 (es) Sales cristalinas de (s)-6-((1-acetilpiperidina-4-yl)amino)-n-(3-(3,4-dihidroisoquinolina-2(1h)-yl)-2-hidroxypropil)pyrimidina-4-carboxamida
IT201600117287A1 (it) Metodo di trasfezione transiente per produzione retrovirale.
EP3541459C0 (fr) Canule, système d'assistance ecmo
CL2019000049A1 (es) Procesos para la preparación de oxipicolinamidas 4 - alkoxi - (acil o aquil).
IL253920A0 (en) Antibodies targeting a galactan-based o-antigen of k. pneumoniae
EP3443299A4 (en) GYROMAGNETIC GEOLOCATION SYSTEM
TR201903795T4 (tr) Ngs si̇stemleri̇ kontrolü ve bunu kapsayan yöntemler
CO2017010143A2 (es) Procesos para preparar fluorocetólidos
IT201600114763A1 (it) Supporto per smartphone.
EA201692246A1 (ru) Способ получения 2,6-диметилбензохинона
CL2016002256A1 (es) Un proceso mejorado para la preparación de exametazima
DK3178329T3 (da) Fremgangsmåde til fremstilling af kvark eller creme fraiche, starterkultur, kvark eller creme fraiche
FR3026718B1 (fr) Systeme de roulage d'un aeronef.
Denkova An aspect on Macedonian language and culture
TH1601003085A (th) เหล็กกล้าที่เป็นแม่เหล็กชั่วคราวและวิธีการสำหรับการผลิตสิ่งเดียวกันนี้, และส่วน ประกอบที่เป็นแม่เหล็กชั่วคราวที่ได้รับมาจากเหล็กกล้าที่เป็นแม่เหล็กชั่วคราว
UA114708U (uk) Тяговий привід електробуса
AU2016900160A0 (en) Magnetic levitating system.